We are pleased to announce that WuXi’s subsidiary, STA Pharmaceutical Co., Ltd, has signed an investment agreement with the government of Shanghai Jinshan District to build a new R&D center. The new facility will further strengthen WuXi STA’s global leading pharmaceutical development and manufacturing platform, enabling drug developers to accelerate their projects from preclinical to commercial stage.
The new R&D center is located next to the existing Jinshan drug substance manufacturing site, and will add more than 30,000 square meters of laboratory space and 500 scientists.
The new R&D center is a reflection of STA’s commitment to better serving its customers worldwide and supporting the growth of local economy as well as the biopharmaceutical ecosystem in Jinshan. As STA continuously strengthens the capability and capacity of its platform, the company will enable more global partners to shorten the time and lower the cost of new drug development, and improve lives of people around the world.